He said: “The UK is leading the way to develop a world-first vaccine for this vomiting bug, starting with this innovative ...

The biotechnology giant has not ruled out expanding its pipeline of treatments through acquisitions after a number of ...

This highly lethal virus, a cousin of Ebola, is striking the country for the first time. Rwanda has received, in three weeks, ...

We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...

Farmers and industry leaders are losing patience and becoming frustrated with this government for holding Defra back, ...

However, Novavax's shares recently dropped by about 20% in one day after it announced a clinical setback. The biotech's stock ...

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain ...

We recently compiled a list of the 8 Best US Stocks For Foreign Investors Right Now. In this article, we are going to take a ...

The third quarter ended with a bang, with all the major indices near record highs as investors shunned macroeconomic ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We spoke with Dr. Demetre Daskalakis, the director of the CDC’s National Center for Immunization and Respiratory Diseases, about the agency’s avian flu response.